The Food and Drug Administration announced Wednesday it will convene a public advisory committee meeting next month to evaluate a drug application for MDMA as a treatment for post-traumatic stress disorder. In a federal notice, the FDA said the Psychopharmacologic Drugs Advisory Committee will discuss the overall benefit-risk profile and …
Weed it and Reap: Cannabis Rescheduling’s Impact on Tax Deductions – JD Supra
New York Cannabis Reguations – Are You a True Party of Interest? According to New Jersey Federal Court, Employees Cannot Sue Under New Jersey Cannabis …